First PREMIER Bank lowered its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.0% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,607 shares of the biopharmaceutical company’s stock after selling 430 shares during the period. First PREMIER Bank’s holdings in Gilead Sciences were worth $1,370,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of GILD. Advisors Preferred LLC acquired a new position in shares of Gilead Sciences during the second quarter worth $26,000. Weaver Consulting Group acquired a new position in shares of Gilead Sciences during the first quarter worth $34,000. Legacy Advisors LLC acquired a new position in shares of Gilead Sciences during the second quarter worth $37,000. Evolution Wealth Advisors LLC acquired a new position in shares of Gilead Sciences during the second quarter worth $46,000. Finally, Motco lifted its holdings in shares of Gilead Sciences by 213.6% during the second quarter. Motco now owns 690 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 470 shares during the period. Hedge funds and other institutional investors own 79.57% of the company’s stock.

GILD traded up $1.30 during midday trading on Thursday, hitting $63.28. The company had a trading volume of 434,377 shares, compared to its average volume of 6,185,329. Gilead Sciences, Inc. has a 52 week low of $60.32 and a 52 week high of $77.06. The company has a quick ratio of 3.67, a current ratio of 3.76 and a debt-to-equity ratio of 1.13. The company has a market capitalization of $79.98 billion, a price-to-earnings ratio of 10.29, a PEG ratio of 2.98 and a beta of 1.10. The stock’s 50 day moving average price is $64.11 and its 200 day moving average price is $65.34.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, beating the consensus estimate of $1.68 by $0.14. Gilead Sciences had a net margin of 26.64% and a return on equity of 37.12%. The firm had revenue of $5.69 billion during the quarter, compared to the consensus estimate of $5.54 billion. During the same period in the previous year, the firm posted $1.91 earnings per share. The business’s revenue was down 2.8% compared to the same quarter last year. Research analysts predict that Gilead Sciences, Inc. will post 6.66 EPS for the current year.

The firm also recently announced a quarterly dividend, which was paid on Friday, September 27th. Stockholders of record on Friday, September 13th were given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 3.98%. The ex-dividend date of this dividend was Thursday, September 12th. Gilead Sciences’s payout ratio is presently 40.98%.

A number of brokerages have recently commented on GILD. Royal Bank of Canada upgraded shares of Gilead Sciences from an “outperform” rating to a “top pick” rating and set a $91.00 price target on the stock in a report on Monday, July 29th. Raymond James set a $85.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Friday, August 23rd. Jefferies Financial Group set a $95.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Monday, July 15th. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a report on Monday, July 15th. Finally, ValuEngine raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research note on Wednesday, October 2nd. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $82.24.

In other news, EVP Brett A. Pletcher sold 7,200 shares of the business’s stock in a transaction dated Tuesday, July 23rd. The shares were sold at an average price of $65.07, for a total transaction of $468,504.00. Following the completion of the sale, the executive vice president now directly owns 34,398 shares of the company’s stock, valued at $2,238,277.86. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Olsen Per Wold sold 4,908 shares of the business’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $63.91, for a total transaction of $313,670.28. Following the sale, the director now directly owns 102,762 shares of the company’s stock, valued at $6,567,519.42. The disclosure for this sale can be found here. Over the last three months, insiders have sold 12,716 shares of company stock valued at $821,299. 0.20% of the stock is currently owned by insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Featured Article: CD Ladder

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.